2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction

Reduced T-Cell Thymic Export Reflected by sj-TREC in Patients with Coronary Artery Disease

“…The diagnosis of CAD 22) was based on the ischemic proofs of electrocardiogram in an appropriate clinical setting (chest discomfort or anginal equivalents) and angiographically proven coronary artery stenosis ( 70%) 23,24) . UA was defined as angina pain at rest lasting for at least 10 min within 24 h before enrollment or more severe and prolonged angina pectoris or angina precipitated by less exertion than in the past and electrocardiographic (ECG) changes compatible with the clinical diagnosis of UA (new ST-segment depression ≥ 0.1 mV and T wave inversion ≥ 0.1 mV in at least two adjacent leads) [25][26][27][28] .…”

Acurácia dos escores GRACE e TIMI na predição da gravidade angiográfica da síndrome coronariana aguda

“…Both scores are commonly used for the clinical decision of patients with ACS, aiming at defining the aggressiveness of the antithrombotic treatment and the either invasive or selective strategy of stratification 14,15 . That use is based on the established prognostic value of those scores and on the relationship between baseline risk and the magnitude of the benefit of certain strategies.…”

Roles of the CHADS2 and CHA2DS2-VASc scores in post-myocardial infarction patients: Risk of new occurrence of atrial fibrillation and ischemic stroke

“…First, the co-occurrence of MI and AF often represents a challenging management problem to the attending physician, particularly when coronary stenting is required. For patients with pre-existing AF who developed MI and were undergoing coronary stenting, current guidelines recommend a combination of aspirin, clopidogrel, and oral anticoagulation, the so-called triple therapy [7,28]. This is because the dual antiplatelet therapy, (aspirin and clopidogrel) essential to prevent stent thrombosis, has been proven inferior to warfarin for the prevention of AF-related ischemic stroke [29,30].…”

“…Nevertheless, as prolonged triple therapy (1 year) is associated with an excessive major bleeding risk [31][32][33], the duration of such therapy should be shortened in order to avoid/minimize bleeding complications. The use of drug-eluting stents in such patients is thus discouraged [28]. Among patients with no pre-existing AF, a drug-eluting stent is often the preferred stent of many interventional cardiologists given the advantages of a small reduction of target vessel revascularization over bare-metal stents [34,35].…”